High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

Increasing the dose of abiraterone at the time of resistance has limited clinical utility and cannot be recommended. Lower baseline circulating androgen levels and interpatient pharmacokinetic variance appear to be associated with primary resistance to AA with P.